Week 96 Results of Switching from Tenofovir Disoproxil Fumarate-Based Antiretroviral Therapy to Coformulated Elvitegravir, Cobicistat, Emtricitabine, and Tenofovir Alafenamide among HIV/Hepatitis B Virus-Coinfected Patients.
Huang YS, Cheng CY, Sun HY, Cheng SH, Lu PL, Lee CH, Lee YT, Tsai HC, Yang CJ, Liu CE, Liou BH, Lin SP, Huang SH, Ho MW, Tang HJ, Hung CC; Taiwan HIV Study Group.
Huang YS, et al. Among authors: cheng sh.
Microbiol Spectr. 2023 Jun 15;11(3):e0512522. doi: 10.1128/spectrum.05125-22. Epub 2023 Mar 29.
Microbiol Spectr. 2023.
PMID: 36988457
Free PMC article.
IMPORTANCE Elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide as a maintenance therapy showed durable and high rates of viral suppression for HIV/HBV-coinfected patients, with only 5.1% and 2.2% of patients having HBV DNA of 20 IU/mL and HIV RNA of 50 copies/mL, respecti …
IMPORTANCE Elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide as a maintenance therapy showed durable and high rates of viral suppr …